Thursday, June 29, 2023 Daily Archives

Xeno-free T cell Expansions in PBS Mini Vertical-Wheel® Bioreactor Using CellGenix® reagents

by

Cell and gene therapies continue to be the fastest growing area of therapeutics, with several new therapies available to patients and hundreds more in development. Sustaining such innovation requires biopharma companies to solve many operational challenges, particularly in manufacturing and scaling up therapies. Cell and gene therapies typically require a substantial amount of cells per dose, which means that bioreactor-based expansion of therapeutically active cells is key. This is the first study that demonstrates the cultivation of T cells in…

June 29, 2023

Wood wins $50m GSK deal to sustain specialized meds manufacturing

by

GSK has awarded consulting and engineering firm Wood $50 million to sustain production of critical medicines at its Maryland plant. GlaxoSmithKline (GSK) said the investment is part of the company’s US capital project, which aims to sustain the global biopharma’s manufacture of critical speciality medicines. Under the terms of the three-year contract, Wood will act as the capital project delivery partner and provide engineering, procurement, construction, and validation (EPCMV) services for GSK’s site in Rockville, Maryland. “As the need for…

June 29, 2023

Pharmadule to provide modular facilities in Singapore for WuXi Bio

by

The partnership will see Pharmadule Morimatsu deliver modular facilities for CDMO WuXi Biologics at its Singapore plant. Pharmadule, a company focused on delivering pharmaceutical manufacturing facilities, will initially begin the partnership with the integrated modular plant of two production facilities at contract development manufacturing organization (CDMO) WuXi Biologics’ Singapore center. Pharmadule will be responsible for the design, production, installation, commissioning, and the validation of the modular plants. Additionally, the company will build, assemble, and carry out Facility Acceptance Testing (FAT)…

June 29, 2023

Astraveus exits stealth mode with $18m to advance CGT platform

by

Astraveus has launched and will use the $18 million in funding to advance development of its microfluidic CGT manufacturing platform. According to the Paris-based firm Astraveus, its Lakhesys cell and gene therapy (CGT) manufacturing platform is “revolutionizing” the space. The platform uses deep process optimization as well as single-use, microfluidic bioprocessors to produce improved results with decreased inputs. The microfluidic bioprocessors mimic organ perfusion and significantly speed up the molecular interactions required to uphold and transform cells into potent therapeutic…

June 29, 2023